Colesevelam: A review of its use in hypercholesterolemia

American Journal of Cardiovascular Drugs

Volumn 7, Issue 6, 2007, Pages 453-465

  Robinson, Dean M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Hyperlipidaemia

Indexed keywords

ATORVASTATIN; COLESEVELAM; FENOFIBRATE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADD ON THERAPY; BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; EMBASE; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MEDLINE; MONOTHERAPY; MORNING DOSAGE; MYALGIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW;

EID: 37149030919     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707060-00009     Document Type: Review

References (47)

1. Yusuf S, Reddy S, Ôunpuu S, et al. Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001 Nov; 104 (22): 2746-53
2. Graham I, Atar D, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007 Aug 28; 28: 2375-414
3. American Heart Association. Heart disease and stroke statistics: 2006 update (at-a-glance version) [online]. Available from URL: http://www. americanheart.org/downloadable/heart/1140534985281Statsupdate06book.pdf [Accessed 2007 Aug 25]
4. Tolonen H, Keil U, Ferrario M, et al. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA project. Int J Epidemiol 2005; 34 (1): 181-92
5. European Medicines Agency. Summary of product characteristics (Cholestagel) [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/cholestagel/H-512-PI-en.pdf [Accessed 2006 Jul 30]
6. Daiichi Sankyo Inc. WelChol® tablets (colesevelam hydrochloride) prescribing information [online]. Available from URL: http://www.welchol.com/ pdfs/fullPI.pdf [Accessed 2006 Oct 25]
7. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005 Jul-Aug; 12 (4): 306-10
8. Bays HE, Rhyne J, Abby S, et al. Lipid lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006 Oct; 22 (11): 2191-200
9. Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007 Jan-Feb; 13 (1): 11-6
10. Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006 Dec; 55 (12): 1697-703
11. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the Glucose-lowering effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007 Jan; 29 (1): 74-83
12. Daiichi Sankyo, Inc. announces filing of supplemental new drug application for Welchol in the treatment of type 2 diabetes mellitus [media release]. Daiichi Sankyo, Inc., 2007 Jan 2
13. Heller DP, Burke SK, Davidson DM, et al. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002 Mar; 36: 398-403
14. Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drug 2001; 1 (2): 141-6
15. Rosenbaum DP, Petersen JS, Ducharme S, et al. Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. J Pharm Sci 1997 May; 86 (5): 591-5
16. Donovan JM, Von Bergmann K, Setchell KDR, et al. Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005 Jul; 50 (7): 1232-8
17. Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam and other bile acid sequestrants. Polymer Reprints 2000; 41 (1): 708-9
18. Center for Drug Evaluation and Research. Application number: 21-141 and 21-176 pharmacological review(s) [online]. Available from URL: http://www.access-data.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2006 Aug 28]
19. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999 Sep 13; 159 (16): 1893-900
20. Insull Jr W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76 (10): 971-82
21. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001 Jun; 24: 467-74
22. Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006 Apr 15; 97 (8): 1198-205
23. Hunninghake D, Insull W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001 Oct; 158: 407-16
24. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110 (5): 352-60
25. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005 Sep; 21 (9): 1403-12
26. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000 Dec; 14 (6): 681-90
27. Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002 Mar; 36: 392-7
28. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004; 43 (13): 943-50
29. Sankyo Pharma. Colesevelam hydrochloride clinical executive summary. Rockville (MD): Sankyo Pharma, 2000. (Data on file)
30. European Medicines Agency. Scientific discussion (Cholestagel) [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/cholestagel/ 586403en6.pdf [Accessed 2006 Jul 30]
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366 (9493): 1267-78
32. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
33. Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev Cardiovasc Ther 2006 May; 4 (3): 283-91
34. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 Feb 28; 160 (4): 459-67
35. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39
36. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006 Jul; 21 (4): 400-4
37. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90 (10 Suppl. 2): 50K-60K
38. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24 (8): 729-41
39. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf [Accessed 2006 Sep 20]
40. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 Jan 20; 251 (3): 351-64
41. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995 Apr 27; 332 (17): 1125-31
42. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998 Mar 1; 81 (5): 582-7
43. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006 Apr 17; 97 (8A): 44C-51C
44. Tardif JC, Heinonen T, Orloff D, et al. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006; 113 (25): 2936-42
45. The lipid research clinics coronary primary prevention trial results. II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251 (3): 365-74
46. Dorr AE, Gundersen K, Schneider Jr JC, et al. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis 1978 Jan; 31 (1): 5-14
47. The lipid research clinics coronary primary prevention trial results. I: reduction in incidence of coronary heart disease. JAMA 1984; 251 (3): 351-64